Campus Virchow Klinikum | Cranach Haus, 13353 Berlin

Our Services

Do you want to accelerate attainment of approval for new, innovative drug candidates and minimize the development risks?

CheckImmune is an innovative service company offering the full biomarker package, from consulting and laboratory services to scientific and medical data interpretation, with a focus on immunology.

Selection/validation of drug lead candidates

You have developed one or more lead candidates for immunotherapies and want to know more about the mode-of-action, their effect on patient cells, and possible side effects (immunotoxicity).

CheckImmune offers a broad portfolio of human in vitro test systems on various technology platforms to address your questions.

Phase 0 studies

You want to implement a new biomarker program for your clinical trials - CheckImmune offers test development and validation as well as Proof-of-Concept on biosamples of the target patient population to pre-test feasibility, stability, and significance but also to confirm putative patient group stratification markers. Recruitment of patients can be supported by our strong clinical and academic network.

Therapy monitoring (safety, efficacy/stratification)

You want to obtain the maximum amount of information about the effect of your drug candidate in clinical studies (first-in-human up to pivotal phase III studies) with the help of the biomarker program – CheckImmune offers a broad portfolio of qualified or validated assays (off-the-shelf and highly customized tests) on various technology platforms in the accredited FDA/EMA-compatible study laboratory to capture safety aspects, pharmacokinetics, pharmacodynamics, stratification of patient groups, mode-of-action and putative patient stratification for follow-up studies.

Data analysis and scientific & medical interpretation

You want to analyze and understand the clinical and biomarker data obtained in your trials – CheckImmune offers support in bioinformatic analysis as well as scientific and medical interpretation of the data with its long-standing experiences and expertise in clinical biomarker studies.

Would you like to talk to us?